Once Daily, Oral Nonpeptide Somatostatin Receptor Type 2 (SST2) Specific Agonist Paltusotine is Associated with Long-Term Toleration and Efficacy in Patients with Acromegaly Enrolled in ACROBAT Advance, a Phase 2 Open Label Extension Study

Saturday, May 14, 2022

11:45 AM – 12:00 PM

Location: Learning Lab B - AACE Learning Zone

Submitter(s)

Participants should be aware of the following financial/non-financial relationships:

Alessandra Casagrande: Disclosure information not submitted.